利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

429 条记录 (耗时 0.027 秒)

    Culture medium for cell growth and transfection
    93.
    发明公开
    Culture medium for cell growth and transfection 审中-公开
    KulturmediumfürZellwachstum und Transfektion

    公开(公告)号：EP2351827A1

    公开(公告)日：2011-08-03

    申请号：EP10175462.0

    申请日：2002-03-27

    申请人： Life Technologies Corporation

    发明人： Ciccarone, Valentina ,  Gruber, Dale ,  Bennett, Shelly

    IPC分类号： C12N1/00 ,  C12N5/00

    CPC分类号： C12N9/2471 ,  C12N5/0018 ,  C12N5/0043 ,  C12N5/005 ,  C12N15/88 ,  C12N2500/22 ,  C12N2500/24 ,  C12N2501/999 ,  C12N2510/02

    摘要： The present invention is directed generally to cell culture media (particularly serum free, non animal derived, and/or chemically defined media) which are useful for introducing macromolecules and compounds (e.g., nucleic acid molecules) into cells (e.g., eukaryotic cells). According to the invention, such introduction can take place in the presence of said medium. Cells containing such introduced materials can then be cultured in the medium and the effect of the introduced materials on the cells can be measured or determined. In particular, the invention allows introduction of nucleic acid molecules (e.g., vectors) into cells (particularly eukaryotic cells) and expression of proteins encoded by the nucleic acid molecules in the cells. The invention obviates the need to change the cell culture medium each time a different procedure is performed with the cells (e.g., culturing cells vs. transfecting cells). The invention thus provides efficient and high throughput methods to transform/transfect culture and cells avoiding the need for multiple manipulations and transfers of cells during transfection and expression studies. The invention also relates to compositions and kits useful for culturing and transforming/transfecting cells.

    摘要翻译： 本发明一般涉及可用于将大分子和化合物（例如，核酸分子）引入细胞（例如真核细胞）中的细胞培养基（特别是无血清，非动物衍生和/或化学界定的培养基）。 根据本发明，这种引入可以在所述介质的存在下进行。 然后可以在培养基中培养含有这种引入的物质的细胞，并且可以测量或测定引入的细胞对细胞的影响。 特别地，本发明允许将核酸分子（例如，载体）引入细胞（特别是真核细胞）中，以及由核酸分子在细胞中表达的蛋白质的表达。 本发明消除了在每次用细胞（例如，培养细胞与转染细胞）进行不同程序时改变细胞培养基的需要。 因此，本发明提供了有效和高通量的方法来转化/转染培养物和细胞，避免了在转染和表达研究期间对细胞的多次操作和转移的需要。 本发明还涉及可用于培养和转化/转染细胞的组合物和试剂盒。

    Method for in vitro recombination
    94.
    发明公开
    Method for in vitro recombination 有权
    Verfahren zur体外重组

    公开(公告)号：EP2239327A2

    公开(公告)日：2010-10-13

    申请号：EP10168787.9

    申请日：2006-08-11

    申请人： Synthetic Genomics, Inc.

    发明人： Gibson, Daniel Glenn ,  Smith, Hamilton, O.

    IPC分类号： C12N15/09 ,  C12N15/00

    CPC分类号： C12N9/1252 ,  C12N15/10 ,  C12N15/102 ,  C12N15/1031 ,  C12N15/64 ,  C12N15/66 ,  C12P19/34

    摘要： The present invention relates to an in vitro method for joining a first set of double-stranded (ds) DNA molecules, comprising:
    (a) providing two or more dsDNA molecules to be joined, wherein, for each pair of dsDNA molecules to be joined, the distal region of the first DNA molecule and the proximal region of the second DNA molecule share a region of sequence homology comprising at least about 20 non-palindromic nucleotides;
    (b) treating the provided dsDNA molecules with a substantially purified enzyme having 5'-3' exonuclease activity, whereby single-stranded overhanging portions are generated in the dsDNA molecules by 5'-3' exonuclease digestion, wherein each overhanging portion contains the region of homology or a portion thereof sufficient to specifically hybridize to the overhanging portion in the other molecule of the pair;
    (c) incubating the DNA molecules generated in step (b), under conditions whereby they anneal through the overhanging portions; and
    (d) treating the annealed molecules with a substantially purified DNA polymerase and a substantially purified compatible ligase, under conditions whereby remaining single-stranded gap(s) are filled in by the polymerase and nicks are sealed by the ligase;

    thereby joining the dsDNA molecules, wherein the method is carried out in the presence of a crowding agent ,e.g. about 5% PEG.

    摘要翻译： 本发明涉及一种用于连接第一组双链（ds）DNA分子的体外方法，其包括：（a）提供两个或更多个待连接的dsDNA分子，其中，对于待连接的每对双链DNA分子 所述第一DNA分子的远侧区域和所述第二DNA分子的近端区域共享包含至少约20个非回归性核苷酸的序列同源性区域; （b）用具有5'-3'核酸外切酶活性的基本上纯化的酶处理所提供的dsDNA分子，由此通过5'-3'外切核酸酶消化在dsDNA分子中产生单链突出部分，其中每个悬伸部分包含区域 的同源性或其一部分足以与该对的另一个分子中的突出部分特异性杂交; （c）在步骤（b）中产生的DNA分子在通过悬伸部分退火的条件下孵育; 和（d）在基本上纯化的DNA聚合酶和基本上纯化的相容性连接酶的条件下处理退火的分子，其中由聚合酶填充剩余的单链间隙，并且切口用连接酶密封; 从而连接dsDNA分子，其中所述方法在拥挤剂存在下进行，例如， 约5％PEG。

    Protein kinase c peptide modulators of angiogenesis
    97.
    发明公开
    Protein kinase c peptide modulators of angiogenesis 审中-公开
    蛋氨酸酶C-肽肽血管生成素

    公开(公告)号：EP2194124A1

    公开(公告)日：2010-06-09

    申请号：EP10158274.0

    申请日：2006-09-19

    申请人： Kai Pharmaceuticals, Inc.

    发明人： Chen, Leon ,  Walter, Sarah ,  Macelan, Derek

    IPC分类号： C12N9/12 ,  A61K38/45

    CPC分类号： C12Y207/11013 ,  A61K9/0048 ,  A61K9/08 ,  A61K38/00 ,  A61K47/645 ,  C12N9/1205

    摘要： The present invention provides peptides for inhibiting various protein kinase C isozymes. The peptide can be directed to any region of the protein kinase C isozyme, and in one embodiment, is directed to the V5 domain. The peptide can be conjugated to a carrier, in a releasable or non-releasable manner. The peptides can be used to inhibit angiogenesis and/or vascular permeability. The peptides can be used to treat subjects having, for example, cancer, diabetic blindness, macular degeneration, rheumatoid arthritis, or psoriasis.

    摘要翻译： 本发明提供用于抑制各种蛋白激酶C同功酶的肽。 肽可以被引导到蛋白激酶C同功酶的任何区域，并且在一个实施方案中，涉及V5结构域。 肽可以以可释放或不可释放的方式与载体缀合。 肽可用于抑制血管生成和/或血管通透性。 所述肽可用于治疗患有例如癌症，糖尿病性失明，黄斑变性，类风湿性关节炎或牛皮癣的受试者。

    METHODS TO IDENTIFY BIOLOGICALLY ACTIVE AGENTS AND SYNERGISTIC COMBINATIONS
    98.
    发明授权
    METHODS TO IDENTIFY BIOLOGICALLY ACTIVE AGENTS AND SYNERGISTIC COMBINATIONS 有权
    一种用于识别生物活性剂协同组合

    公开(公告)号：EP1606759B1

    公开(公告)日：2010-05-05

    申请号：EP04758254.9

    申请日：2004-03-24

    申请人： Synergy Biosystems Ltd.

    发明人： SCOTT, Ian, R.

    IPC分类号： G01N33/50 ,  G06F19/00

    CPC分类号： G01N33/48 ,  C40B30/06 ,  G06F19/704

    摘要： Methods are described using a particular type of assay system, the Multi-Pathway High Throughput Assay, in conjunction with a novel experimental strategy, whereby repeated cycles of experiments result in the identification of the most effective synergistic combinations of potential active agents from a library of materials. The novel experimental strategy not only requires far fewer total experiments than would be required using conventional discovery strategies but also maximizes the probability of finding highly synergistic combinations through the principle of multiple-pathway intervention.